智通财经网·2026-02-27 02:28Core Viewpoint - 康龙化成 is experiencing a positive market reaction, with a stock increase of over 3% and a current price of 19.76 HKD, driven by optimistic forecasts regarding its upcoming 2025 full-year performance and accelerated order growth [1] Group 1: Company Performance - 花旗 has initiated a 90-day positive catalyst observation for 康龙化成, highlighting the upcoming announcement of the company's 2025 full-year results as a key catalyst [1] - The report indicates that 康龙化成 is expected to become a leading indicator of customer demand recovery, providing clearer guidance for future revenue growth [1] - 花旗's earnings per share forecast for 康龙化成 is 4% higher than the market consensus for this fiscal year [1] Group 2: Industry Position - 康龙化成 is recognized as a global leader in drug research and development, benefiting from the growth trend in China's CRO industry [1] - The company is not only maintaining its leadership in drug research but is also expanding into downstream late-stage clinical development and commercial production, as well as venturing into the biopharmaceutical sector [1]